In this edition of Null and Noteworthy, tests of intranasal oxytocin and an Angelman syndrome treatment fail to see results.

The post Null and Noteworthy: Null rejection, repetitive behaviors, unsuccessful treatments appeared first on Spectrum | Autism Research News.

An autism brain imaging study published seven years ago received an expression of concern last month after its authors failed to uphold a promise to make their raw data freely available.

The post Autism study earns ‘expression of concern’ over unavailable data appeared first on Spectrum | Autism Research News.

Studies of autism subtypes rarely validate their results, and this has led to a proliferation of autism subtypes of questionable utility. But reliable subtyping can help improve the prognosis for and care of autistic people.

The post Validating autism subtypes: A crucial but often overlooked step in research appeared first on Spectrum | Autism Research News.

Conflicts of interest and methodological issues sully a study published 18 July in the Journal of Autism and Developmental Disorders, autism researchers say.

The post Contentious study prompts backlash from autism researchers appeared first on Spectrum | Autism Research News.

In this edition of Null and Noteworthy, researchers open the case on acetaminophen and close it on oxytocin.

The post Null and Noteworthy: Oxytocin, parental training, outcome assessments appeared first on Spectrum | Autism Research News.

PS: The Aspergian is now called NeuroClastic. We were recently asked by Terra from the Aspergian to become a contributor to their platform, and we are happy to join them. You may now call us the Embracian (I’m kidding). United Indeed, we have a platfor...